Cascade genetic testing: an underutilized pathway to equitable cancer care?

Area of Science:

• Genomics
• Precision Medicine
• Cancer Genetics

Background:

• The Precision Medicine Initiative leverages genomic data for personalized healthcare.
• Cascade genetic testing facilitates the dissemination of familial genomic risk information.
• Germline pathogenic mutations, particularly those linked to hereditary cancers, necessitate familial risk assessment.

Purpose of the Study:

• To describe cascade genetic testing as a key component of precision medicine.
• To highlight the role of cascade testing in hereditary cancer prevention.
• To explore the potential of cascade testing in medically underserved populations.

Main Methods:

• Review of cascade genetic testing principles and applications.
• Focus on familial diffusion of cancer-associated germline pathogenic mutations.
• Examination of implications for primary disease prevention strategies.

Main Results:

• Cascade testing identifies at-risk relatives for hereditary cancer syndromes.
• It enables genetically targeted interventions like surveillance and risk-reducing surgery.
• The Centers for Disease Control and Prevention recognizes it as a Tier 1 genomic application for hereditary breast and ovarian cancer.

Conclusions:

• Cascade genetic testing is a critical tool for precision medicine in oncology.
• It offers significant benefits in reducing morbidity and mortality from hereditary cancers.
• Its application holds promise for improving healthcare equity in vulnerable populations.